Canada Tech CEOs Urge ‘Real Debate' on Economy Ahead of Vote
Canadian technology leaders are calling for a 'real debate' about the country's economic future when party leaders discuss their views on stage next week.
'For too long, Canadian government leaders have prioritized short-term economic interests and photo ops over investment into Canada's economic well-being,' reads a letter signed by 150 chief executive officers including Coveo Solutions Inc.'s Louis Têtu, Stingray Group Inc. 's Eric Boyko and Lightspeed Commerce Inc. 's Dax Dasilva.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
12 minutes ago
- Business Upturn
Ahmedabad Air India Plane Crash: Former Gujarat CM Vijay Rupani confirmed dead
In a heartbreaking development, it has now been reportedly confirmed that former Gujarat Chief Minister Vijay Rupani was among the victims of the Air India flight AI171 crash near Ahmedabad on Wednesday, June 12. Parimal Nathwani, Member of Parliament in the Rajya Sabha, had earlier posted a condolence message on social media confirming the demise of former Gujarat Chief Minister Vijay Rupani in the tragic Air India plane crash near Ahmedabad. However, the tweet was subsequently deleted, sparking speculation and raising questions about the official status of Rupani's presence on the flight and his condition. Authorities have yet to release an official confirmation, and the situation remains unclear. Rupani, along with several members of his team, was onboard the Boeing 787 Dreamliner aircraft that was operating the Ahmedabad to London (Gatwick) route. The plane crashed shortly after takeoff from the Sardar Vallabhbhai Patel International Airport, falling in the Meghani Nagar area, causing a massive blaze and widespread destruction. Initial reports had speculated Rupani's presence on the passenger manifest, which was later verified by both state authorities and Air India sources. The confirmation marks a deep political and personal loss for the state and the country. Rupani, a prominent BJP leader, served as Gujarat's Chief Minister from 2016 to 2021. As per official data, the aircraft was carrying 242 individuals, including 53 British nationals, 169 Indian nationals, 1 Canadian, and 7 Portuguese citizens. The Directorate General of Civil Aviation (DGCA) confirmed the plane gave a MAYDAY call moments after takeoff but failed to respond thereafter. The Indian government has initiated a high-level inquiry into the incident, and Prime Minister Narendra Modi has dispatched senior ministers to oversee the response efforts in Ahmedabad. More updates are awaited as rescue and recovery operations continue. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Associated Press
27 minutes ago
- Associated Press
Theralase Completes Annual General and Special Meeting
Toronto, Ontario--(Newsfile Corp. - June 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ('Theralase®" or the 'Company'), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, is pleased to announce the successful completion of its Annual General and Special Meeting ('AGSM'), which was held on Wednesday, June 11 th, 2025, at the Company's head office in Toronto, Ontario, Canada. Following shareholder approval on various resolutions and formal conclusion of the AGSM meeting, Theralase® hosted a virtual corporate presentation via Zoom to provide shareholders with an in-depth overview of the Company's strategic objectives and upcoming milestones for 2025 and 2026. The presentation highlighted current and planned clinical development programs focused on accelerating the commercialization of Theralase®'s innovative therapeutic technologies. For those unable to attend the live virtual session, an archived recording of the presentation can be accessed via the following link: Watch the AGSM Virtual Presentation here: AGSM Virtual Presentation Recording - Presented June 11th, 2025 Theralase® wishes to thank its shareholders and stakeholders for their ongoing support as the Company advances on its mission to commercialize safe and effective therapeutics to destroy various cancers, bacteria and viruses, with minimal impact on healthy tissue. About Theralase® Technologies Inc.: Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. Additional information is available at and Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward Looking Statements This news release contains Forward-Looking Statements ('FLS') within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words 'may, 'should', 'will', 'anticipates', 'believes', 'plans', 'expects', 'estimate', 'potential for' and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals. These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission, acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict. Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS. Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS. All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS. For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies. For More Information: (843-5273) (5273) Kristina Hachey, CPA Chief Financial Officer X 224 [email protected] To view the source version of this press release, please visit
Yahoo
31 minutes ago
- Yahoo
Canadian Politician Reveals How 'Gangster' Trump's Imminent Visit Has Triggered Alarm
Canadian politician Charlie Angus ― a fierce critic of Donald Trump ― delivered a blistering rebuke of the U.S. president ahead of his planned attendance of the G-7 summit in Kananaskis, Alberta, next week. Angus slammed Trump as a 'gangster president.' And the ex-lawmaker claimed to have received hundreds of messages from Canadians who are angered that a convicted felon and man 'who has threatened our nation's sovereignty is being allowed into our country.' 'I understand [Canadian Prime Minister Mark] Carney's reluctance to escalate the situation with the MAGA president but we have to stop kidding ourselves and be honest about what we are being asked to engage with,' warned Angus, a member of the left-leaning New Democratic Party who retired from his role in the Canadian Parliament in March. Trump poses a 'clear threat to American democracy, to Canadian sovereignty and to the international rule of law,' he added, noting the U.S. president's repeated attacks on Canada amid his bid to turn it into the 51st state. Angus also pointed out the stark difference between Trump's aggression towards America's northern neighbor and his relatively softer stance on Russia and its authoritarian, war-mongering President Vladimir Putin. 'Canada can no longer view the United States as an ally,' Angus said. At another point, he warned: 'We can't kid ourselves about the threat that's being posed by Donald Trump.' Watch Angus' full speech here: Terry Moran Reveals What's Next After Trump Slam Led To Exit From ABC News Trump Ducks 'Les Misérables' Character Question, Internet Brutally Answers It For Him 'Daily Show' Audience Erupts Over Desi Lydic's Trump Parade Realization
